Long-term observation of vitrectomy without subretinal hemorrhage management for massive vitreous hemorrhage secondary to polypoidal choroidal vasculopathy

AIM: To describe the long-term observation of vitrectomy without subretinal hemorrhage (SRH) management for massive vitreous hemorrhage (VH) secondary to polypoidal choroidal vasculopathy (PCV). METHODS: This is a retrospective, consecutive case series. A total of 86 eyes of 86 patients with >14d of massive VH associated with PCV were included. All patients underwent vitrectomy without SRH management, followed by intravitreal ranibizumab injections and/or photodynamic therapy (PDT) as needed. The main outcome measures were best-corrected visual acuity (BCVA), postoperative adverse events and the recurrence of VH. RESULTS: The average follow-up period was 25.5±9.2mo (range 12-35mo). Mean BCVA at baseline (2.16±0.39 logMAR) had improved significantly, both 3mo after surgery (1.42±0.66 logMAR, P<0.001) and by the last visit (1.23±0.74 logMAR, P<0.001). The common postoperative complications included macular subretinal fibrosis in 14 eyes (16.3%) and ciliary body detachment in 4 eyes (4.7%). Nineteen eyes (22.1%) received following treatment with ranibizumab injections without/with PDT, and 15 (17.4%) were resolved. Four eyes (4.7%) had recurrent hemorrhage during the follow-up period. In multiple regression analysis, thicker SRH (beta=0.33, P=0.025) in the preoperative B-scan and the presence of foveal subretinal fibrosis (beta=0.28, P=0.018) in the follow up were associated with poor postoperative BCVA. CONCLUSION: Vitrectomy without SRH management for massive VH secondary to PCV improved/stabilized visual function in the long-term observation. Eyes presenting with thicker SRH preoperatively and forming foveal subretinal fibrosis in the follow-up period tended to have worse BCVA.     

Verteporfin photodynamic therapy of six eyes with retinal capillary haemangioma

Acta Ophthalmol. 2010: 88: e334–e340

Abstract.

Purpose: Single‐centre consecutive interventional case series by retrospective chart review to evaluate the efficacy of verteporfin (Visudyne?) photodynamic therapy (PDT) of retinal capillary haemangioma (RCH). Methods: Following an initial period of observation, six eyes of five patients with RCH (juxtapapillary 3 and extrapapillary (EP) 3) received 1–3 sessions of standard verteporfin PDT upon the development of progressive vision‐threatening complications. Four of the five patients had von Hippel‐Lindau (VHL) disease. Follow‐up included documentation of best‐corrected Snellen visual acuity (BCVA), tumour regression, and presence or absence of subretinal fluid (SRF) and/or lipid exudation as assessed by dilated fundus examination (DFE), fundus photos, and optical coherence tomography (OCT). These parameters were documented at 1 week, 1 month, and 3 months following each PDT session and up to 32 months following the first PDT. Results: All eyes showed favourable response to PDT as defined by tumour regression or stabilization as well as improvement of SRF and lipid exudation. BCVA improved or stabilized in three eyes. Three eyes required PDT retreatment for recurrent SRF. Epiretinal membrane (ERM) worsened in three eyes, requiring vitreoretinal surgery at a median of 6 months following PDT. Conclusions: PDT is a moderately effective treatment for juxtapapillary and EP RCH. In this series, PDT resulted in tumour regression or stabilization as well as in the improvement of SRF and lipid exudation in all cases. However, stabilization or improvement of visual acuity was observed in only 50 per cent of the cases. The treatment benefits may be limited by pre‐existing macular changes and worsening of ERM. A larger prospective study is necessary to validate these findings.     

Recurrent bleeding after photodynamic therapy in polypoidal choroidal vasculopathy

PURPOSE: To report a case of recurrent bleeding after photodynamic therapy (PDT) in an eye with polypoidal choroidal vasculopathy (PCV). DESIGN: Interventional case report. METHODS: A 73-year-old man was treated in the left eye for PCV with PDT. RESULTS: Two weeks after PDT, his left eye showed extensive subretinal hemorrhage, with a slight vision loss. Three months after PDT, subretinal hemorrhage was almost absorbed. He received a second session of PDT to the remaining choroidal neovascularization. Two weeks thereafter, his left eye showed massive suprachoroidal hemorrhage with further vision loss. One month after the second PDT, visual acuity was decreased to no light perception as a result of massive vitreous hemorrhage. Although the patient underwent pars plana vitrectomy, visual acuity in the left eye remained hand motion as a result of massive suprachoroidal hemorrhage. CONCLUSIONS: Ophthalmologists and patients should be aware of the risk of massive bleeding after PDT in eyes with PCV.     

眼底血管样条纹并发脉络膜新生血管的临床特征及联合治疗

目的 分析眼底血管样条纹（AS）并发CNV的临床特征,探讨光动力疗法（PDT）联合玻璃体腔注射雷珠单抗治疗AS合并黄斑病变的临床疗效及安全性。方法 回顾性系列病例研究。分析21例（42眼）AS的临床资料,包括BCVA、眼底表现、FFA、ICGA以及OCT。其中18例（22眼）合并黄斑CNV,先采用PDT治疗,3 d内玻璃体腔注射雷珠单抗,治疗后定期随访,至少随访12个月。随访时如发现视力下降、黄斑区出现新病灶、视网膜下或层间积液、CNV活动性病变,则重复玻璃体腔注射。数据采用独立样本t检验或配对样本t检验进行分析。结果 本组21例患者均双眼发病,仅5例（24%）合并全身病变,男性为主（76%）,其中18例（86%）继发黄斑CNV,BCVA显著低于病变未侵及黄斑者。联合治疗的22眼末次随访时BCVA较治疗前提高10.4个字母;OCT示治疗后黄斑区视网膜厚度从基线的（338.4±55.2）μm降至（212.6±36.2）μm;FFA（ICGA）显示15眼（68%）CNV完全闭合,渗漏消失,5眼呈瘢痕染色。所有患者接受1次PDT,平均玻璃体腔注射次数3.2次。1例PDT后出现黄斑区视网膜下出血,行玻璃体腔注射雷珠单抗后出血吸收,5例发生一过性眼压升高,4例出现结膜下出血,均完全恢复,无其他明显眼部及全身不良反应。结论 眼底AS具有特殊的眼底表现,FFA（ICGA）有助于明确诊断,相当比例的患者可继发黄斑部CNV。PDT联合玻璃体腔注射雷珠单抗能有效控制AS合并黄斑病变的病情进展,显著改善患者视功能,减少CNV渗漏,且不良反应少。     

Study of the causes of poor visual prognosis in photodynamic therapy for age-related macular degeneration

PURPOSE: To study the factors for poor visual outcome in photodynamic therapy(PDT) for age-related macular degeneration (AMD) patients with subfoveal choroidal neovascularization. MATERIALS AND METHODS: Medical charts of eighty-five patients (88 eyes) who had AMD with subfoveal choroidal neovascularization were reviewed in the study. All patients were followed up by visual acuity assessment, angiography, and optical coherence tomography at least 6 months after PDT. RESULTS: Out of 11 cases of poor visual outcome, 7 cases showed cystoid macular edema (CME) before treatment and 4 cases showed massive subretinal hemorrhage and/or vitreous hemorrhage after treatment. Some cases with CME had a worse visual outcome than cases without CME. CONCLUSIONS: Some of the factors for poor visual outcome after PDT for AMD are the existence of CME before treatment and polypoidal choroidal vasculopathy (PCV). In some cases, PCV caused massive subretinal hemorrhage and/or vitreous hemorrhage after treatment.     

应用1/3剂量光动力学疗法治疗急性CSC

观察1/3剂量光动力学疗法（photodynamic therapy, PDT）治疗急性中心性浆液性脉络膜视网膜病变（central serous chorioretinopathy, CSC）的短期疗效。 方法：选取急性CSC患者26例26眼,行单次1/3量维替泊芬（2mg/m2）进行PDT治疗,术前和术后1,4,12wk进行最佳矫正视力和OCT的检测,且于术前、术后4wk和12wk进行眼底荧光素血管造影（FFA）,吲哚青绿血管造影（ICG）检查,观察治疗的有效性和安全性。 结果：术后1wk,26眼中有20眼（77%）视网膜下积液吸收,其余6眼（23%）视网膜下液部分吸收;术后4wk,26眼视网膜下积液全部吸收,22眼荧光渗漏完全消失,脉络膜血管高渗透性消失;术后12wk,26眼均病情平稳,无复发。治疗后1wk,最佳矫正视力从术前平均0.41升高至0.80。随访期间26眼均未见任何不良反应。 结论：1/3剂量PDT治疗急性 CSC短期内安全有效     

Choroidal hemangioma treated with photodynamic therapy using verteporfin: report of a case

PURPOSE: To report the results of treatment of circumscribed choroidal hemangioma with a single application of photodynamic therapy (PDT) with verteporfin according to the Treatment of Age-related Macular Degeneration with Photodynamic Therapy study. METHODS: A 44-year-old man with unilateral decreased vision and macular subretinal fluid secondary to a circumscribed choroidal hemangioma diagnosed by fluorescein and indocyanine green angiography and ultrasonography underwent PDT with verteporfin therapy. RESULTS: One year after PDT, subretinal fluid was absent and visual acuity improved. CONCLUSIONS: The results obtained in this case are in keeping with previously reported results; however, future randomized studies are necessary to evaluate and standardize different infusion times in order to obtain maximum efficacy of treatment.     

光动力疗法治疗卵黄样黄斑营养不良并发脉络膜新生血管临床观察

目的 观察光动力疗法(PDT)治疗卵黄样黄斑营养不良(VMD)并发脉络膜新生血管(CNV)的临床疗效.方法 回顾性分析行PDT治疗的7例VMD并发CNV患者7只眼的临床资料.患者中男性4例,女性3例.年龄20～54岁.治疗前后行最佳矫正视力(BCVA)、裂隙灯显微镜、眼底彩色照相、荧光素眼底血管造影(FFA)、吲哚青绿血管造影(ICGA)、频域光相干断层扫描(SD-OCT)以及眼电图( EOG)、视网膜电图(ERG)等检查.患眼BCVA数指/眼前～0.6;光感受器内外节(IS/OS)界面下积液,视网膜水肿,平均中央视网膜厚度(506.00±30.71) μm.PDT治疗按照标准常规操作完成.治疗后随访2～11个月,平均随访时间6.3个月.观察BCVA及CNV变化以及与治疗相关的副作用.结果 末次随访时,患眼BCVA 0.12～1.0,均有不同程度提高;FFA及ICGA检查显示,CNV萎缩变小,渗漏减轻;SDOCT检查见神经视网膜水肿减轻或消退,平均中央视网膜厚度下降为(401.00±52.22) μm,IS/OS界面与视网膜色素上皮间光反射暗区消失,黄斑恢复基本正常形态;未见与治疗相关的局部及全身副作用发生.结论 PDT能有效治疗VMD并发的CNV,稳定或提高患者视力.     

组合光斑光动力疗法治疗孤立性脉络膜血管瘤的疗效和安全性观察

目的 观察组合光斑光动力疗法(PDT)治疗孤立性脉络膜血管瘤的疗效和安全性.方法 为回顾性系列病例研究.经眼底镜、荧光素眼底血管造影、眼底彩色照相及B超检查,确诊孤立性脉络膜血管瘤患者10例,均只行一次组合光斑PDT治疗.术前最佳矫正视力为眼前数指至0.3,B超检查肿瘤最大直线距离为5.5～9.9 mm,平均6.8 mm;最大厚度1.1～3.8 mm,平均2.7 mm,4例伴视网膜脱离.PDT治疗为注射用维替泊芬6 mg/m2体表面积,10 min推注完毕,5 min后行689 nm激光照射,激光参数50 J/cm2,时间83 s.光斑大小3～5 mm,治疗2～3个光斑,根据肿瘤大小及形状治疗光斑可以部分重叠,术后随访3.0～15.0个月,平均8.5个月.结果 组合光斑PDT治疗后最后一次随访视力为眼前数指至1.0,7例患者提高2行以上,3例稳定.其中2例B超检查提示肿瘤测不出.8例肿瘤最大厚度0.5～2.7 mm,平均1.9 mm,最大直线距离4.2～8.3 mm,平均6.4 mm,2例视网膜脱离消失,有视网膜色素上皮改变.结论 组合光斑PDT治疗孤立性脉络膜血管瘤安全有效,可以使瘤体萎缩,视网膜脱离消失或减轻,视力提高.     

光动力疗法与经瞳孔温热疗法治疗孤立型脉络膜血管瘤的疗效观察

目的 观察经瞳孔温热疗法(TTT)和光动力疗法(PDT)治疗孤立型脉络膜血管瘤(CCH)的疗效.方法 回顾性分析经眼底检查、荧光素眼底血管造影(FFA)、吲噪青绿血管造影(ICGA)、光相干断层扫描(OCT)、眼部B型超声检查确诊为CCH的患者32例33只眼的临床资料.所选病例治疗前最佳矫正视力为指数/眼前～0.2,瘤体大小2～10个视盘直径(DD),均有浆液性视网膜脱离.其中21例22只眼CCH位于除乳斑柬及黄斑拱环内区域外的后极部采用经瞳孔温热疗法(TTT)治疗.使用Iris 810 nm半导体红外激光,能量700～1200 mw,时间60 S,光斑1～3个不等;11例11只眼CCH位于乳斑束及黄斑拱环以内区域的PDT治疗.经静脉注射维速达尔15 min后采用689 nm波长半导体激光对病灶进行照射83～123 s.随访时间12～48个月,平均随访时间为25.6个月.治疗后复查视力、间接检眼镜、彩色眼底照像、FFA、ICGA、OCT和B型超声波检查,观察其疗效.结果 TTT治疗22只眼中,15只眼视力提高,7只眼视力稳定,眼底检查见视网膜平复,瘤体呈灰白色机化瘢痕,造影显示病灶无荧光渗漏,晚期机化瘢痕处呈荧光染色.OCT检查显示22只眼视网膜神经上皮脱离消失,视网膜下积液完全吸收,其瘤体部脉络膜光带反射增强,瘢痕形成;B型超声检查显示22只眼无视网膜脱离,瘤体萎缩.PDT治疗11只跟中9只眼视力提高,2只眼视力稳定,眼底检查见瘤体萎缩,色素沉着,造影显示荧光渗漏消失;OCT显示视网膜下液完全吸收,B型超声检查11只眼瘤体萎缩.结论 TTT与PDT治疗CCH有效但适用部位有所不同.两种方法均可使瘤体萎缩,稳定或提高患者的视力.     

A Large Retinal Capillary Hemangioma in the Anterior Retina Treated with Photodynamic Therapy

Purpose

To report a case of a large anterior retinal capillary hemangioma (RCH) treated successfully with photodynamic therapy (PDT).

Methods

Case report.

Results

A 12-mm-large RCH located in the anterior retina, with vision-threatening exudative complications that had not responded to cryotherapy and repeated laser photocoagulations, was treated with PDT using verteporfin. Exudation regressed and tumor growth arrested after treatment.

Conclusion

PDT can be delivered effectively to a lesion in the anterior retina and should be included as an option for treating anteriorly located RCH when conventional cryotherapy and laser photocoagulation fail.Key words: Retinal capillary hemangioma, Photodynamic therapy, Subretinal fluid     

Comparison of fluorescein angiography and optical coherence tomography for patients with choroidal neovascularization after photodynamic therapy

PURPOSE: To investigate retinal morphology by means of fluorescein angiography (FA) and optical coherence tomography (OCT) in patients who had undergone photodynamic therapy (PDT) with verteporfin at their 3-month-interval examination. METHODS: Sixty patients with predominantly classic choroidal neovascularization (CNV) secondary to age-related macular degeneration were evaluated with FA and OCT 3 months after their last PDT. FA images were evaluated in a masked fashion for staining of and leakage from the lesion and also for cystoid loculation of fluorescein in the macula. OCT was used to evaluate foveal thickness and the presence of subretinal fluid or cystoid spaces within the retina, also in a masked fashion. RESULTS: The median age of the 60 patients was 78 years, and the median visual acuity of the eyes examined was 20/100. The median number of previous PDT sessions was 2. Fluorescein staining was seen in 57 eyes (95%), and fluorescein leakage was seen in 50 eyes (83%). Cystoid loculation of fluorescein was seen in 21 eyes (35%). By OCT, cystoid spaces in the macula were seen in 42 patients (70%), and subretinal fluid was seen in 15 patients (25%). Leakage seen shown by FA was correlated with the OCT finding of cystoid spaces but not with the OCT finding of subretinal fluid. Some patients had leakage during FA that did not have any observable induced OCT abnormality attributable to fluid accumulation. CONCLUSIONS: After PDT leakage from CNV seen during FA is associated with intraretinal fluid, often seen in loculated cystoid spaces, but not with subretinal fluid.     

The development of recurrent choroidal neovascularization in a patient with choroidal coloboma

We report a case of recurrent choroidal neovascularization (CNV) in an eye with chorioretinal coloboma. A 36-year-old woman presented complaining of decreased visual acuity (VA) in her left eye. Best corrected visual acuity (BCVA) was 20/200 and iris coloboma was observed. Funduscopy and fluorescein angiography (FA) showed CNV in the superior extrafoveal region with chorioretinal coloboma reaching just inferior to the optic disc. No other cause for CNV was observed except for the chorioretinal coloboma. BCVA improved to 20/30 after laser photocoagulation. She revisited our clinic for deteriorating VA (20/400) in the same eye 3 years after treatment. Funduscopy and FA demonstrated recurrent CNV with subfoveal hemorrhage. Photodynamic therapy (PDT) was followed by three consecutive intravitreal bevacizumab injections (IVB) for the subfoveally-located CNV. However, the CNV persisted with the appearance of a fresh subretinal hemorrhage. Additional PDT was combined with IVB on the same day 6 months after the initial PDT. The CNV regressed 3 months after treatment and has not recurred as of 8 months after the last treatment. The patient's BCVA improved to 20/60. This case suggests that PDT combined with IVB can be an alternative treatment for the management of recurrent CNV after laser photocoagulation in eyes with chorioretinal coloboma.     

Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy

PURPOSE: To evaluate the clinical features and risk factors of hemorrhagic complications in eyes with polypoidal choroidal vasculopathy (PCV) after photodynamic therapy (PDT). METHODS: We retrospectively reviewed data for 91 consecutive eyes of 85 patients who underwent PDT for the treatment of PCV. The diagnosis of PCV was based on indocyanine green angiographic findings, showing a branching vascular network terminating in polypoidal swelling. The greatest linear dimension included all polypoidal lesions, leaking vascular network, and type 2 choroidal neovascularization. RESULTS: During the follow-up period after PDT, postoperative subretinal hemorrhage was seen in 28 (30.8%) of 91 eyes. In 22 (78.6%) of these 28 eyes, subretinal hemorrhage was absorbed without treatment. In 6 eyes (21.4%), however, bleeding resulted in vitreous hemorrhage, and 2 eyes underwent pars plana vitrectomy. Although visual acuity was maintained or increased in 18 (81.8%) of 22 eyes with subretinal hemorrhage alone, it decreased significantly in 3 (50.0%) of 6 eyes with postoperative vitreous hemorrhage. Various systemic diseases and medication with an anticoagulant had no correlation with these hemorrhagic complications. Laser irradiation spot size for PDT was significantly larger in eyes with postoperative vitreous hemorrhage (P = 0.017) than in those without. CONCLUSION: Subretinal hemorrhage after PDT can be a common complication in patients with PCV and may have a minor effect on visual outcome. However, postoperative hemorrhage is occasionally so massive that it leads to vitreous hemorrhage and poor visual prognosis. When considering PDT for eyes with a large PCV lesion, ophthalmologists should be aware of the risk of serious hemorrhagic complications.     

Photodynamic therapy for retinal capillary hemangioma

Purpose

To describe the results of photodynamic therapy (PDT) for juxtapapillary and peripheral retinal capillary hemangioma (RCH).

Patients and methods

Interventional case series of four eyes (four patients) with juxtapapillary RCH and one eye (one patient) with peripheral RCH. Two eyes with juxtapapillary RCH had received two sessions of full-fluence, double-duration PDT; whereas other two eyes had received single session of half-fluence, single-duration PDT. The peripheral RCH was treated with a single session of full-fluence, single-duration PDT.

Results

Two patients had von Hippel–Lindau disease. Follow-up duration ranged from 4 months to 1 year. Pre-PDT visual acuity (VA) ranged from 20/200 to HM (juxtapapillary RCH) and 20/100 (peripheral RCH). Among the eyes with juxtapapillary RCH, tumor regression with partial resolution of macular edema was noted in two eyes (one eye each with half-fluence and full-fluence PDT), whereas two eyes had no change in tumor size with persistent macular edema. VA remained stable in three eyes and declined in one eye. In an eye with peripheral RCH, regression of tumor and macular edema with VA improvement was noted. Post-PDT complications included epiretinal membrane (one eye) and transient exudative retinal detachment (one eye).

Conclusion

PDT can be effective in reducing macular edema associated with RCH but this does not always correspond with an improvement in VA especially for juxtapapillary tumors.     

Ultra Q:YAG与传统Nd:YAG激光对视网膜内界膜下出血患者治疗效果的对比

目的　通过多模式影像联合对比观察Ultra Q:YAG与传统Nd:YAG激光对视网膜内界膜下出血患者积血引流的治疗效果。方法　回顾性分析我院确诊为视网膜内界膜下出血的患者共18例18眼的临床资料，接受Ultra Q:YAG激光内界膜切开引流术者9例9眼为A组，接受传统Nd:YAG激光内界膜切开引流术者9例9眼为B组。所有患者均行视力、眼底照相、B型超声及OCT检查，无全身禁忌证者行荧光素眼底血管造影（FFA）检查。比较两组治疗前及治疗后1 h、1 d、1周、2周的最佳矫正视力（BCVA）、黄斑中心凹视网膜厚度（CMT）。结果　治疗后1周，A组患眼视网膜内界膜下出血均已完全吸收；治疗后2周，B组患眼视网膜内界膜下出血均已完全吸收。治疗前及治疗后1 h、2周，A组与B组患眼间BCVA及CMT相比差异均无统计学意义（均为P＞0.05）；治疗后1 d、1周，A组患眼BCVA、CMT均较B组改善更明显，两组相比差异均有统计学意义（均为P<0.05）。结论　相较于传统Nd:YAG激光，Ultra Q:YAG激光内界膜切开引流术治疗视网膜内界膜下出血更为安全有效。     

低剂量PDT治疗中心性浆液性脉络膜视网膜病变

目的：观察低剂量光动力学疗法(photodynamic therapy, PDT)治疗中心性浆液性脉络膜视网膜病变(central serous chorioretinopathy, CSC)的短期疗效。

方法：选取急性CSC患者36例36眼,进行单次1/2量维替泊芬(3mg/m²)进行PDT治疗,分别于术前和术后1,4,12,24wk进行最佳矫正视力和OCT的检查,术前、术后4,24wk进行FFA和ICG检查。

结果：术后1wk,36眼中有27眼(75%)OCT显示视网膜下积液完全吸收,其余9眼(25%)视网膜下液部分吸收; 术后4wk,36眼视网膜下积液全部吸收,FFA+ICG示36眼荧光渗漏完全消失,脉络膜血管高渗透性消失; 术后12～24wk,36眼无复发。治疗后4wk,最佳矫正视力从术前平均0.52提高至0.80。随访期间36眼未见任何不良反应。

结论：低剂量PDT治疗CSC短期内安全有效,能缩短病程,显著提高视力。     

Management of peripheral polypoidal choroidal vasculopathy with intravitreal bevacizumab and indocyanine green angiography-guided laser photocoagulation

A 69-year-old lady presented with complaints of decreased vision in left eye since one month. Best Corrected Visual Acuity (BCVA) was 6/18 in that eye. Fundus examination revealed non-central geographic atrophy and soft drusens at macula in both eyes. Temporal periphery of left eye revealed subretinal exudates with altered sub-RPE hemorrhage mimicking peripheral exudative hemorrhagic chorioretinopathy (PEHCR). Fundus Fluorescein Angiogram showed window defects at macula and blocked fluorescence at temporal periphery in left eye. However, Indocyanine green angiography (ICGA) revealed active peripheral choroidal polyps. The patient was successfully treated with intravitreal bevacizumab and ICGA-guided laser photocoagulation. 27 months after laser treatment, BCVA improved to 6/9. Rationale of consecutive anti-vascular endothelial growth factor (VEGF) treatment followed by more definitive laser photocoagulation is that anti-VEGF aids in resolution of subretinal fluid, thus making the polyp more amenable to focal laser photocoagulation which stabilizes the choroidal vasculature and prevents further leakage.     

A case of circumscribed choroidal hemangioma in Sturge-Weber syndrome in China

We present a case of circumscribed choroidal hemangioma (CCH) in Sturge-Weber syndrome in a 30-year-old woman with congenital port-wine stains on the left side of face involving the upper eyelid, cheek and the nose, and she had undergone facial hemangioma surgery 3 years ago suggestive of Sturge-Weber syndrome. She presented with a 1-month history of rapidly decreased visual acuity (VA) to counting fingers in the left eye which had no prior history of visual problem. And there was no evidence of glaucoma. At 3 months after the treatment of the standard photodynamic therapy (PDT) the VA was 20/200. For some reasons, we have no idea about the changes of tumor thickness and subretinal fluid. We confirmed the curative effect of PDT treatment for CCH because of the significantly improved VA in the bad eye.     

视盘毛细血管瘤激光治疗的疗效观察

目的 探讨激光治疗视盘毛细血管瘤的临床疗效。 设计 回顾性病例系列。研究对象 视盘毛细血管瘤患者11 例12眼。方法 所有患者接受一种或两种激光的联合治疗,包括传统激光（波长532 nm绿光或波长577 nm黄光）光凝及光动力学疗法（PDT）,其中5眼采用传统激光直接光凝瘤体,4眼采用PDT治疗, 3眼采用PDT联合传统激光光凝。治疗1~7次,平均（3.3±2.1）次。随访时间2~132个月,平均（42.5±41.8）个月。激光治疗前后检查患者视力,间接检眼镜观察瘤体变化、视网膜下液、出血、前膜等情况。主要指标 视力、瘤体大小、视网膜下液、出血、前膜等。结果 11例12眼中,治疗前视力为指数/30cm～1.0,其中视力≥0.5者3眼,<0.5且≥0.1者5眼,<0.1者4眼;治疗后末次随访时视力为眼前手动~1.0,其中视力≥0.5者1眼,<0.5且≥0.1者7眼,<0.1者4眼。治疗后8眼瘤体萎缩机化,1眼瘤体无变化,3眼瘤体继续增长。8眼视网膜下液减少或完全吸收,3眼视网膜下液持续增加;5眼治疗后继发视网膜前膜,4眼继发黄斑区色素沉着。结论 适时采取单纯或多种激光联合治疗可有效控制视盘毛细血管瘤的进展。